Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L. Berry; Francis L. Munier; Brenda L. Gallie; Ashley Polski; Sona Shah; Carol L. Shields; Dan S. Gombos; Kathleen Ruchalski; Christina Stathopoulos; Rachana Shah; Rima Jubran; Jonathan W. Kim; Prithvi Mruthyunjaya; Brian P. Marr; Matthew W. Wilson; Rachel C. Brennan; Guillermo L. Chantada; Murali M. Chintagumpala; A. Linn Murphree

doi:10.1002/pbc.28964

Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L. Berry, Francis L. Munier, Brenda L. Gallie, Ashley Polski, Sona Shah, Carol L. Shields, Dan S. Gombos, Kathleen Ruchalski, Christina Stathopoulos, Rachana Shah, Rima Jubran, Jonathan W. Kim, Prithvi Mruthyunjaya, Brian P. Marr, Matthew W. Wilson, Rachel C. Brennan, Guillermo L. Chantada, Murali M. Chintagumpala, A. Linn Murphree

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression-free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

Original language	English (US)
Article number	e28964
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	5
DOIs	https://doi.org/10.1002/pbc.28964
State	Published - May 2021

Keywords

clinical trials
imaging
ocular oncology
response criteria
retinoblastoma
ultrasonography

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.28964

Cite this

Berry, J. L., Munier, F. L., Gallie, B. L., Polski, A., Shah, S., Shields, C. L., Gombos, D. S., Ruchalski, K., Stathopoulos, C., Shah, R., Jubran, R., Kim, J. W., Mruthyunjaya, P., Marr, B. P., Wilson, M. W., Brennan, R. C., Chantada, G. L., Chintagumpala, M. M., & Murphree, A. L. (2021). Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatric Blood and Cancer, 68(5), Article e28964. https://doi.org/10.1002/pbc.28964

Berry, JL, Munier, FL, Gallie, BL, Polski, A, Shah, S, Shields, CL, Gombos, DS, Ruchalski, K, Stathopoulos, C, Shah, R, Jubran, R, Kim, JW, Mruthyunjaya, P, Marr, BP, Wilson, MW, Brennan, RC, Chantada, GL, Chintagumpala, MM & Murphree, AL 2021, 'Response criteria for intraocular retinoblastoma: RB-RECIST', Pediatric Blood and Cancer, vol. 68, no. 5, e28964. https://doi.org/10.1002/pbc.28964

@article{996fd37c6254465ca75c9312c4443930,

title = "Response criteria for intraocular retinoblastoma: RB-RECIST",

abstract = "Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression-free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.",

keywords = "clinical trials, imaging, ocular oncology, response criteria, retinoblastoma, ultrasonography",

author = "Berry, {Jesse L.} and Munier, {Francis L.} and Gallie, {Brenda L.} and Ashley Polski and Sona Shah and Shields, {Carol L.} and Gombos, {Dan S.} and Kathleen Ruchalski and Christina Stathopoulos and Rachana Shah and Rima Jubran and Kim, {Jonathan W.} and Prithvi Mruthyunjaya and Marr, {Brian P.} and Wilson, {Matthew W.} and Brennan, {Rachel C.} and Chantada, {Guillermo L.} and Chintagumpala, {Murali M.} and Murphree, {A. Linn}",

note = "Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC",

year = "2021",

month = may,

doi = "10.1002/pbc.28964",

language = "English (US)",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Response criteria for intraocular retinoblastoma

T2 - RB-RECIST

AU - Berry, Jesse L.

AU - Munier, Francis L.

AU - Gallie, Brenda L.

AU - Polski, Ashley

AU - Shah, Sona

AU - Shields, Carol L.

AU - Gombos, Dan S.

AU - Ruchalski, Kathleen

AU - Stathopoulos, Christina

AU - Shah, Rachana

AU - Jubran, Rima

AU - Kim, Jonathan W.

AU - Mruthyunjaya, Prithvi

AU - Marr, Brian P.

AU - Wilson, Matthew W.

AU - Brennan, Rachel C.

AU - Chantada, Guillermo L.

AU - Chintagumpala, Murali M.

AU - Murphree, A. Linn

PY - 2021/5

Y1 - 2021/5

N2 - Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression-free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

AB - Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response—such as progression-free survival—to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

KW - clinical trials

KW - imaging

KW - ocular oncology

KW - response criteria

KW - retinoblastoma

KW - ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=85101208757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101208757&partnerID=8YFLogxK

U2 - 10.1002/pbc.28964

DO - 10.1002/pbc.28964

M3 - Article

C2 - 33624399

AN - SCOPUS:85101208757

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 5

M1 - e28964

ER -

Response criteria for intraocular retinoblastoma: RB-RECIST

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this